A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223

被引:779
|
作者
Wang, Kun [1 ]
Long, Bo [2 ,3 ]
Liu, Fang [4 ]
Wang, Jian-Xun [1 ]
Liu, Cui-Yun [1 ]
Zhao, Bing [1 ]
Zhou, Lu-Yu [1 ]
Sun, Teng [1 ]
Wang, Man [1 ]
Yu, Tao [1 ]
Gong, Ying [1 ]
Liu, Jia [1 ]
Dong, Yan-Han [1 ]
Li, Na [1 ]
Li, Pei-Feng [1 ]
机构
[1] Qingdao Univ, Inst Translat Med, Coll Med, Ctr Dev Cardiol, Qingdao 266021, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Cent Res Lab, Lab Mol Med, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100730, Peoples R China
[4] Guilin Med Univ, Dept Anat, Coll Basic Med, Guilin 541004, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Circular RNA; HRCR; Cardiac hypertrophy; Heart failure; CASPASE RECRUITMENT DOMAIN; MUSCLE-SPECIFIC MICRORNA; CARDIAC-HYPERTROPHY; APOPTOSIS REPRESSOR; CARDIOMYOCYTE HYPERTROPHY; CELL PROLIFERATION; SKELETAL-MUSCLE; DIFFERENTIATION; OVEREXPRESSION; TRANSCRIPTS;
D O I
10.1093/eurheartj/ehv713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our present study reveals a novel cardiac hypertrophic regulating model that is composed of circRNA, miR-223, and ARC. Modulation of their levels may provide a new approach for tackling cardiac hypertrophy and heart failure. Our present work advances our understanding about the role of circRNAs and miRNAs in cardiac hypertrophy and heart failure. Circular RNA may represent a potential new therapeutic strategy to attenuate the pathogenesis of cardiac diseases.Sustained cardiac hypertrophy accompanied by maladaptive cardiac remodelling represents an early event in the clinical course leading to heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. However, the molecular mechanisms that regulate cardiac hypertrophy are largely unknown. Here we show that a circular RNA (circRNA), which we term heart-related circRNA (HRCR), acts as an endogenous miR-223 sponge to inhibit cardiac hypertrophy and heart failure. miR-223 transgenic mice developed cardiac hypertrophy and heart failure, whereas miR-223-deficient mice were protected from hypertrophic stimuli, indicating that miR-223 acts as a positive regulator of cardiac hypertrophy. We identified ARC as a miR-223 downstream target to mediate the function of miR-223 in cardiac hypertrophy. Apoptosis repressor with CARD domain transgenic mice showed reduced hypertrophic responses. Further, we found that a circRNA HRCR functions as an endogenous miR-223 sponge to sequester and inhibit miR-223 activity, which resulted in the increase of ARC expression. Heart-related circRNA directly bound to miR-223 in cytoplasm and enforced expression of HRCR in cardiomyocytes and in mice both exhibited attenuated hypertrophic responses. These findings disclose a novel regulatory pathway that is composed of HRCR, miR-223, and ARC. Modulation of their levels provides an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.
引用
收藏
页码:2602 / U24
页数:11
相关论文
共 50 条
  • [31] VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats
    Samuelsson, Anne-Maj
    Bartolomaeus, Theda Ulrike Patricia
    Anandakumar, Harithaa
    Thowsen, Irene
    Nikpey, Elham
    Han, Jianhua
    Marko, Lajos
    Finne, Kenneth
    Tenstad, Olav
    Eckstein, Johannes
    Berndt, Nikolaus
    Kuehne, Titus
    Kedziora, Sarah
    Sultan, Ibrahim
    Skogstrand, Trude
    Karlsen, Tine, V
    Nurmi, Harri
    Forslund, Sofia K.
    Bollano, Entela
    Alitalo, Kari
    Muller, Dominik N.
    Wiig, Helge
    CARDIOVASCULAR RESEARCH, 2023, 119 (07) : 1553 - 1567
  • [32] Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy
    Suckau, Lennart
    Fechner, Henry
    Chemaly, Elie
    Krohn, Stefanie
    Hadri, Lahouaria
    Kockskaemper, Jens
    Westermann, Dirk
    Bisping, Egbert
    Ly, Hung
    Wang, Xiaomin
    Kawase, Yoshiaki
    Chen, Jiqiu
    Liang, Lifan
    Sipo, Isaac
    Vetter, Roland
    Weger, Stefan
    Kurreck, Jens
    Erdmann, Volker
    Tschope, Carsten
    Pieske, Burkert
    Lebeche, Djamel
    Schultheiss, Heinz-Peter
    Hajjar, Roger J.
    Poller, Wolfgang C.
    CIRCULATION, 2009, 119 (09) : 1241 - 1252
  • [33] Heart failure: Targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment
    Latronico, Michael V. G.
    Elia, Leonardo
    Condorelli, Gianluigi
    Catalucci, Daniele
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (09) : 1643 - 1648
  • [34] Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure
    Qian, Ke
    Tang, Jie
    Ling, Yue-Juan
    Zhou, Ming
    Yan, Xin-Xin
    Xie, Yu
    Zhu, Lu-Jia
    Nirmala, Koju
    Sun, Kang-Yun
    Qin, Zheng-Hong
    Sheng, Rui
    EBIOMEDICINE, 2023, 98
  • [35] Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure
    Mallaredy, Vandana
    Roy, Rajika
    Cheng, Zhongjian
    Thej, Charan
    Benedict, Cindy
    Truongcao, May
    Joladarashi, Darukeshwara
    Magadum, Ajit
    Ibetti, Jessica
    Cimini, Maria
    Gonzalez, Carolina
    Garikipati, Venkata Naga Srikanth
    Koch, Walter J.
    Kishore, Raj
    CIRCULATION RESEARCH, 2024, 135 (02) : 280 - 297
  • [36] Differential mRNA Expression and Circular RNA-Based Competitive Endogenous RNA Networks in the Three Stages of Heart Failure in Transverse Aortic Constriction Mice
    Li, Xiang
    Tan, Weijiang
    Zheng, Shuang
    Pyle, W. Glen
    Zhu, Caiyi
    Chen, Honghua
    Kang, Le
    Wu, Jian
    Zou, Yunzeng
    Backx, Peter H.
    Yang, Feng Hua
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [37] MiR-125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure
    Zhang, Bei
    Mao, Shanyong
    Liu, Xingde
    Li, Sha
    Zhou, Haiyan
    Gu, Ying
    Liu, Wupeng
    Fu, Lei
    Liao, Chunyan
    Wang, Pengzhen
    MOLECULAR MEDICINE, 2021, 27 (01)
  • [38] Differential expression of 14-3-3ε during physiological, pathological cardiac hypertrophy and chronic heart failure in mice
    Qi, Jianyong
    Xu, Ming
    Lu, Zhizhen
    Zhang, Youyi
    GENE THERAPY AND MOLECULAR BIOLOGY, 2009, 13A : 71 - 81
  • [39] Transition from compensated hypertrophy to systolic heart failure in the spontaneously hypertensive rat: Structure, function, and transcript analysis
    Brooks, Wesley W.
    Shen, Steven S.
    Conrad, Chester H.
    Goldstein, Ronald H.
    Bing, Oscar H. L.
    GENOMICS, 2010, 95 (02) : 84 - 92
  • [40] Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223
    Dai, Jian
    Xu, Lijuan
    Hu, Xiaohui
    Han, Guodong
    Jiang, Haitao
    Sun, Hailang
    Zhu, Guotai
    Tang, Xiaoming
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 106 : 1441 - 1447